@article{Briegel2021,
  author    = {Briegel, Wolfgang},
  title     = {Psychiatric comorbidities in 1p36 deletion syndrome and their treatment — a case report},
  series = {International Journal of Environmental Research and Public Health},
  volume    = {18},
  journal   = {International Journal of Environmental Research and Public Health},
  number    = {22},
  issn      = {1660-4601},
  doi       = {10.3390/ijerph182212064},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-250189},
  year      = {2021},
  abstract  = {1p36 deletion syndrome represents the most common terminal deletion observed in humans. Major clinical findings comprise developmental delay/intellectual disability, poor or absent expressive language, congenital central muscular hypotonia, brain anomalies, brachydactyly/camptodactyly, short feet, and characteristic facial features like straight eyebrows, deep-set eyes, and midface hypoplasia. So far, there is very limited knowledge about comorbid psychiatric disorders and their effective treatment in this special population. To fill this gap, this case report presents an initially four-year-old girl with 1p36.33-1p36.32 deletion, moderate intellectual disability, insomnia, oppositional-defiant disorder and attention deficit/hyperactivity disorder covering a period of time of about 1.5 years comprising initial psychological/psychiatric assessment, subsequent day clinic/outpatient treatment (amongst others including off-label use of melatonin and methylphenidate as well as parent-child interaction therapy) and follow-up assessment. Follow-up results indicated good efficacy of melatonin and methylphenidate medication without any adverse effects. Multidisciplinarity in diagnosis and treatment are mandatory to meet needs of patients with complex genetic disorders like 1p36 deletion syndrome. Off-label use of melatonin (for insomnia) and methylphenidate (for attention deficit/hyperactivity disorder) should be considered in young children with 1p36 deletion syndrome if behavioral interventions are not sufficient.},
  language  = {en}
}
@article{DarwishAttia2012,
  author    = {Darwish, Hany W. and Attia, Mohamed I.},
  title     = {New spectrofluorimetric methods for determination of melatonin in the presence of N-{2-[1-({3-[2-(acetylamino)ethyl]-5-methoxy-1H-indol-2-yl}methyl)-5-methoxy-1H-indol-3-yl]ethyl} acetamide: a contaminant in commercial melatonin preparations},
  series = {Chemistry Central Journal},
  volume    = {6},
  journal   = {Chemistry Central Journal},
  number    = {36},
  doi       = {10.1186/1752-153X-6-36},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-134606},
  year      = {2012},
  abstract  = {Background: Melatonin (MLT) has many health implications, therefore it is of valuable importance to develop specific analytical methods for determination of MLT in the presence of its main contaminant, N-{2-[1-({3-[2(acetylamino)ethyl]-5-methoxy-1H-indol-2-yl}methyl)-5-methoxy-1H-indol-3-yl]ethyl}acetamide (10). For development of these analytical methods, compound 10 had to be prepared in an adequate amount. Results: Compound 10 was synthesized in six steps starting from 5-methoxyindole-2-carboxylic acid (1). Analytical performance of the proposed spectrofluorimetric methods was statistically validated with respect to linearity, accuracy, precision and specificity. The proposed methods were successfully applied for the assay of MLT in laboratory prepared mixtures containing up to 60 \% of compound 10 and in commercial MLT tablets with recoveries not less than 99.00 \%. No interference was observed from common pharmaceutical additives and the results were favorably compared with those obtained by a reference method. Conclusions: This work describes simple, sensitive, and reliable second derivative spectrofluorimetric method in addition to two multivariate calibration methods, principal component regression (PCR) and partial least square (PLS), for the determination of MLT in the presence of compound 10.},
  language  = {en}
}
@article{GrubisicHaimBhusaletal.2019,
  author    = {Grubisic, Maja and Haim, Abraham and Bhusal, Pramod and Dominoni, Davide M. and Gabriel, Katharina M. A. and Jechow, Andreas and Kupprat, Franziska and Lerner, Amit and Marchant, Paul and Riley, William and Stebelova, Katarina and van Grunsven, Roy H. A. and Zeman, Michal and Zubidat, Abed E. and H{\"o}lker, Franz},
  title     = {Light Pollution, Circadian Photoreception, and Melatonin in Vertebrates},
  series = {Sustainability},
  volume    = {11},
  journal   = {Sustainability},
  number    = {22},
  issn      = {2071-1050},
  doi       = {10.3390/su11226400},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-193095},
  year      = {2019},
  abstract  = {Artificial light at night (ALAN) is increasing exponentially worldwide, accelerated by the transition to new efficient lighting technologies. However, ALAN and resulting light pollution can cause unintended physiological consequences. In vertebrates, production of melatonin—the "hormone of darkness" and a key player in circadian regulation—can be suppressed by ALAN. In this paper, we provide an overview of research on melatonin and ALAN in vertebrates. We discuss how ALAN disrupts natural photic environments, its effect on melatonin and circadian rhythms, and different photoreceptor systems across vertebrate taxa. We then present the results of a systematic review in which we identified studies on melatonin under typical light-polluted conditions in fishes, amphibians, reptiles, birds, and mammals, including humans. Melatonin is suppressed by extremely low light intensities in many vertebrates, ranging from 0.01-0.03 lx for fishes and rodents to 6 lx for sensitive humans. Even lower, wavelength-dependent intensities are implied by some studies and require rigorous testing in ecological contexts. In many studies, melatonin suppression occurs at the minimum light levels tested, and, in better-studied groups, melatonin suppression is reported to occur at lower light levels. We identify major research gaps and conclude that, for most groups, crucial information is lacking. No studies were identified for amphibians and reptiles and long-term impacts of low-level ALAN exposure are unknown. Given the high sensitivity of vertebrate melatonin production to ALAN and the paucity of available information, it is crucial to research impacts of ALAN further in order to inform effective mitigation strategies for human health and the wellbeing and fitness of vertebrates in natural ecosystems.},
  language  = {en}
}
@article{ZappFischerDeuschle2017,
  author    = {Zapp, Angela Alexandra and Fischer, Eva Caroline and Deuschle, Michael},
  title     = {The effect of agomelatine and melatonin on sleep-related eating: a case report},
  series = {Journal of Medical Case Reports},
  volume    = {11},
  journal   = {Journal of Medical Case Reports},
  number    = {275},
  doi       = {10.1186/s13256-017-1438-5},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-157805},
  year      = {2017},
  abstract  = {Background: Sleep-related eating may occur in the context of mental illness, sleep disorders, or psychopharmacological treatment. Frequently, sleep-related eating leads to severe weight gain and, so far, there are no treatment options for the condition. Case presentation: We report the case of a 54-year-old white woman with depression, panic disorder, and sleep apnea under treatment with various antidepressants who developed severe sleep-related eating. Her sleep-related eating completely vanished after addition of agomelatine, it reoccurred after cessation of agomelatine, and vanished again after her re-exposure to another melatonergic drug, extended melatonin. Conclusions: This case suggests that melatonergic drugs lead to relief from sleep-related eating, even when the condition occurs in the context of physical and mental disorders as well as psychopharmacological treatment.},
  language  = {en}
}